CK2 inhibitor CX-4945 destabilizes NOTCH1 and synergizes with JQ1 against human T-acute lymphoblastic leukemic cells

Haematologica. 2017 Jan;102(1):e17-e21. doi: 10.3324/haematol.2016.154013. Epub 2016 Oct 6.
No abstract available

Publication types

  • Letter

MeSH terms

  • Azepines / agonists
  • Azepines / pharmacology*
  • Casein Kinase II / antagonists & inhibitors*
  • Casein Kinase II / genetics
  • Casein Kinase II / metabolism
  • Cell Line, Tumor
  • Drug Synergism
  • Female
  • Humans
  • Male
  • Naphthyridines / agonists
  • Naphthyridines / pharmacology*
  • Neoplasm Proteins / antagonists & inhibitors*
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / metabolism*
  • Phenazines
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / metabolism*
  • Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • Protein Stability
  • Receptor, Notch1 / genetics
  • Receptor, Notch1 / immunology*
  • Triazoles / agonists
  • Triazoles / pharmacology*

Substances

  • (+)-JQ1 compound
  • Azepines
  • NOTCH1 protein, human
  • Naphthyridines
  • Neoplasm Proteins
  • Phenazines
  • Receptor, Notch1
  • Triazoles
  • silmitasertib
  • Casein Kinase II